Key Highlights

  • Cue Biopharma reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria.
  • The trial met all primary endpoints and its key secondary endpoint at the 4 mg/kg dose.
  • The 4 mg/kg dose showed 12-week durable off-treatment benefit.
  • A post-hoc analysis showed an edge over omalizumab at Week 28.

Cue Biopharma, Inc. (NASDAQ: CUE) reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria, meeting all primary endpoints and its key secondary endpoint at 4 mg/kg with significant improvements over placebo and a favorable safety profile.

Company Overview

Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of engineered Biologics designed to selectively engage and modulate T cells to treat various diseases, including autoimmune disorders and cancer. The company's proprietary Immuno-STAT platform is designed to directly and selectively engage and modulate specific T cell populations without broadly suppressing the immune system, an approach intended to improve upon the safety and efficacy limitations of earlier-generation immunomodulatory therapies.

The company has applied its Immuno-STAT platform across multiple therapeutic areas, including autoimmune and inflammatory conditions such as chronic spontaneous urticaria, alongside earlier oncology-focused programs, reflecting a broader strategy of leveraging the same core technology platform across different disease areas where selective T cell modulation may provide therapeutic benefit.

What Happened

The 4 mg/kg dose demonstrated 12-week durable off-treatment benefit and a post-hoc edge over omalizumab at Week 28, supporting Phase 2b/3 CSU trials and food allergy development.

Market Reaction

The disclosed information does not include stock price or trading data for Cue Biopharma following the CUE-221 data release.

Outlook

The planned Phase 2b/3 CSU trials, along with continued food allergy development building on the CUE-221 platform, represent the next major disclosed milestones for Cue Biopharma's Immuno-STAT-based pipeline.